NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany. The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in…
Methotrexate for Ulcerative Colitis Yields Mixed Results
NEW YORK (Reuters Health)—Parenteral methotrexate was no better than placebo for achieving steroid-free remission of ulcerative colitis (UC) in the METEOR trial. But the drug should not be abandoned in all UC patients, researchers say. “Although METEOR failed to reach its primary endpoint, an important secondary endpoint was met. Our study suggests that methotrexate should…
Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…
NIH-Funded Trials Dip While Industry Trials Are on the Rise
(Reuters Health)—Every year since 2006 in the U.S., the number of clinical trials funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows. Analyzing the ClinicalTrials.gov database, researchers found that after trial registration became a requirement for publication in major scientific…
Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study
(Reuters)—Kitov Pharmaceuticals Holdings Ltd. said on Tuesday its lead drug, KIT-302, met the main goal of a late-stage study, reducing pain without increasing the risk of heart diseases in patients with osteoarthritis. Israel-based Kitov says its drug does not need to be labeled with health warnings, but will instead say it reduces the risk of…
New SLE Drug May Allow Patients to Reduce Steroid Use
In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…
Drug Approvals Top 2014 High, but R&D Returns Still Struggle
LONDON (Reuters)—The number of new drugs approved in the U.S. this year has already topped last year’s 18-year high, yet large pharmaceutical companies are still struggling to get a decent return on their research dollars. In fact, returns on research and development (R&D) spending by the world’s top drug makers have fallen to just 4.2%,…
Valeant Hires Attorney, Crisis Management Firm as U.S. Scrutiny Mounts
WASHINGTON/NEW YORK (Reuters)—Pharmaceuticals firm Valeant, under mounting pressure from Congress and prosecutors over its drug pricing, has hired an attorney in Washington, D.C., and crisis public relations experts with political connections, according to sources familiar with the matter. The move, confirmed by sources and through documents viewed by Reuters, signals a shift for Valeant Pharmaceuticals,…
Dr. Michael Weinblatt Discusses Current & Future RA Therapies
According to former ACR President Michael Weinblatt, MD, the future of drug therapies for patients with RA rests in the careful and intelligent prescription of current medications and treatment combinations, as well as better patient access through lower costs…
Smarter Regulation Can Help Cut Drug Prices, Says EU Agency Head
LONDON (Reuters)—Europe’s top drug regulator weighed into the medicine pricing debate on Wednesday, arguing a smarter and faster pharmaceutical approval system was needed to help rein in the spiraling cost of new treatments. In exchange for speeding up the approval process, society would expect manufacturers to charge less for innovative medicines, European Medicines Agency (EMA)…
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 120
- Next Page »